Migraine and High Flow Oxygenotherapy at the Emergency Department (MiOx)

Migraine is a common pathology, affecting around 12% of the general population, up to 25% in some cohorts, as well as a significant part of the reasons for emergency room visits. Unlike cluster headaches, the use of high-flow oxygen therapy has not yet been validated in patients with migraine. However, several aspects of its pathophysiology, still studied to this day, suggest that the use of normobaric oxygen could have beneficial effects on migraine attacks: tissue hypoxia, cerebrovascular dysfunction with vasodilation, inflammation, etc. In addition, high-flow oxygen therapy has no significant side effects and almost no contraindication (mainly COPD and other chronic respiratory failure) Its use in the event of a migraine attack would thus allow less recourse to conventional analgesics (with significant side effects for some), a shorter stay in the emergency room, and therefore a benefit in terms of cost and relief for the patient. In this context, the sponsor wish to carry out a multicenter prospective interventional, single-blind randomized placebo-controlled in parallel groups study.

NCT Number	NCT04925414
Lead Sponsor	Centre Hospitalier Universitaire de Nice
Conditions	Migraine
Enrollment	70 participants
Start Date	2023-10-01
Primary Completion	2025-04 (estimated)
Study Completion	2025-04 (estimated)
Updated on ClinicalTrials.gov	2024-11-18